GNLX Genelux Corp
Price (delayed)
$2.54
Market cap
$87.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$81.2M
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our most advanced product
Highlights
GNLX's debt is down by 26% year-on-year and by 8% since the previous quarter
The company's EPS rose by 18% YoY
GNLX's equity is up by 35% YoY but it is down by 21% from the previous quarter
Genelux's quick ratio has decreased by 27% from the previous quarter but it has increased by 27% YoY
GNLX's gross profit has dropped by 95% year-on-year
Genelux's revenue has shrunk by 95% YoY
Key stats
What are the main financial stats of GNLX
Market
Valuations
Earnings
Shares outstanding
34.6M
Market cap
$87.89M
Enterprise value
$81.2M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.34
Price to sales (P/S)
9,985.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,149.74
Revenue
$8,000
Gross profit
$8,000
Operating income
-$31.7M
Net income
-$29.87M
EBIT
-$29.87M
EBITDA
-$28.97M
Free cash flow
-$21.61M
Per share
Balance sheet
Liquidity
EPS
-$0.95
EPS diluted
-$0.95
Free cash flow per share
-$0.69
Book value per share
$0.76
Revenue per share
$0
TBVPS
$1.1
Total assets
$34.72M
Total liabilities
$8.44M
Debt
$1.87M
Equity
$26.27M
Working capital
$24.65M
Debt to equity
0.07
Current ratio
4.57
Quick ratio
4.48
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
-362,075%
Gross margin
100%
Net margin
-373,362.5%
Operating margin
-396,200%
Return on assets
-82.5%
Return on equity
-106.6%
Return on invested capital
-118.7%
Return on capital employed
-107.4%
Return on sales
-373,362.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GNLX stock price
How has the Genelux stock price performed over time
Intraday
-2.31%
1 week
-20.63%
1 month
-39.23%
1 year
-51.62%
YTD
7.63%
QTD
-5.93%
Financial performance
How have Genelux's revenue and profit performed over time
Revenue
$8,000
Gross profit
$8,000
Operating income
-$31.7M
Net income
-$29.87M
Gross margin
100%
Net margin
-373,362.5%
GNLX's gross profit has dropped by 95% year-on-year
Genelux's revenue has shrunk by 95% YoY
The company's operating income fell by 31% YoY and by 9% QoQ
The operating margin has declined by 9% since the previous quarter
Growth
What is Genelux's growth rate over time
Valuation
What is Genelux stock price valuation
P/E
N/A
P/B
3.34
P/S
9,985.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,149.74
The company's EPS rose by 18% YoY
GNLX's equity is up by 35% YoY but it is down by 21% from the previous quarter
GNLX's price to book (P/B) is 26% lower than its last 4 quarters average of 4.6
Genelux's revenue has shrunk by 95% YoY
The price to sales (P/S) is 15% lower than the last 4 quarters average of 12081.4
Efficiency
How efficient is Genelux business performance
Genelux's return on invested capital has surged by 94% YoY
GNLX's ROE is up by 36% YoY
Genelux's return on assets has increased by 21% YoY but it has decreased by 2.9% QoQ
The company's return on sales fell by 8% QoQ
Dividends
What is GNLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GNLX.
Financial health
How did Genelux financials performed over time
The current ratio has declined by 29% since the previous quarter but it has increased by 24% year-on-year
Genelux's quick ratio has decreased by 27% from the previous quarter but it has increased by 27% YoY
GNLX's debt is 93% smaller than its equity
GNLX's debt to equity is down by 46% YoY but it is up by 17% from the previous quarter
GNLX's equity is up by 35% YoY but it is down by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.